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Abstract
Background

Midlife insulin resistance (IR) has previously been shown to be associated with lower cerebral blood
flow (CBF), and is a potentially modifiable risk factor for dementia. The Blood Flow Improvement Trial
(BFiT), NCT03117829 , tested a 12 week carbohydrate restricted diet (CRD) and exercise behavioral
intervention to reverse IR, and aimed to 1) determine the extent to which improving or normalizing
glucose homeostasis improves CBF and cognitive function in individuals with IR, 2) determine whether
participants continue to maintain improved or normalized glycemic control for 6 months, and 3)
determine changes in the human metabolome as individuals improve or normalize IR and glucose
homeostasis through diet and exercise.

Method

Participants were recruited from the Wisconsin Alzheimer’s Disease Research Center and screened for
metabolic risk factor eligibility based on the criteria shown in Table 1. The design involved a 12 week
diet and exercise intervention focused on self‐monitoring to promote adherence. Exercise was
conducted in a supervised group setting 3 days/week for 50 minutes and participants were instructed
to exercise on their own an additional 2 days/week. Participants followed a CRD and monitored their
own blood glucose with the goal of achieving and maintaining fasting blood glucose <100 mg/dL.
Participants underwent baseline, 12 week, and 6 month procedures including urine and blood
labs/metabolomics, cognitive testing, fitness testing, and blood flow imaging via MRI (Table 2).

Result

The enrollment goal was 40 participants. 118 individuals were screened for eligibility, and 72.5% of the
target enrollment was met; of those participants, nearly 80% completed the 12 week intervention. Of
the 23 participants that completed the intervention, mean attendance was 70% for supervised exercise
sessions and 81% for weekly behavioral coaching sessions. Figure 1 summarizes screening, enrollment,
and procedure completion.

Conclusion

IR may be a modifiable risk factor for dementia. The BFiT pilot trial was designed to test the feasibility
of exercise and CRD to reduce IR and improve brain blood flow in middle‐aged adults. Reasonable
enrollment and completion N were achieved. Future analysis will center on barriers to enrollment and
adherence, as well as analysis of the primary and secondary outcome measures.

FIGURE 1

TABLE 1. Metabolic Eligibility Criteria
Option 1
Fasting blood
glucose of 100 mg/dl
or greater

Option 2 (both)
Waist circumference greater than 40
inches for men and 35 inches for
women
Fasting blood glucose of 100 mg/dl
or greater

Option 3 (any 3)
Fasting triglycerides greater than 150
mg/dl
Fasting HDL less than 40 mg/dl for men
and 50 mg/dl for women
Blood pressure greater than 130/85
mm/Hg (systolic and/or diastolic above
the cutoff)
Waist circumference greater than 40
inches for men and 35 inches for women

TABLE 2. Baseline and Post-Intervention Procedures

Procedure
MRI scan

Questionnaires

Details
~45 minute protocol completed on a SIGNA PET/MR 3-Tesla scanner with 8channel head coil. Scans included Arterial Spin Labelling Perfusion, 4D Flow,
Volumetric Tl -wieghted
MRI, and T2FLAIR .
Demographics; Nutrition beliefs; 7-day Physical Activity Recall; Food and Activity
Questionnaire

Cognitive
California Verbal Learning Test II; Delis Kaplan Executive Function System Test
Testing
Exercise Testing 6-minute walk test· Graded maximal exercise test
Clinical visit
Fasting blood and urine sample (12 hour fast); height, weight, anthropomorphic
measures using DC-430U Tanita body composition analyzer scale

